Week in Review: $1.4 Billion in China Life Science Deals and Financings

Deals and Financings Vivo Capital closed its tenth US-China fund, a private equity healthcare fund, at an oversubscribed $635 million, bringing total assets under management to $2.2 billion ; Xynomic, a US-China clinical-stage oncology pharma, will complete a reverse merger with NASDAQ-listed Bison Capital that values Xynomic at $450 million; Hua Medicine of Beijing priced its Hong Kong IPO at the low end of the range to raise $110 million at a valuation of $1.1 billion; 111, Inc., a China retail online/offline pharmacy, completed a US IPO raising $100 million at a $1.1 billion market capitalization; Tianjin Tasly Pharma out-licensed US marketing rights for its angina TCM, currently in US Phase III trials, to Arbor Pharma in a $50 million deal; Zai Lab paid $15 million upfront to acquire greater China rights to Novocure's electric fields therapy for cancer; Cadrock Pty of Australia raised $5 million from an unnamed China investor for clinical trials of a triple-antibiotic as a coronary artery disease treatment; Shanghai Pharma signed a MOU with Russian biotech BIOCAD to form JVs that manufacture and develop BIOCAD's biologic/biosimilar drugs for China ; Trials and Approvals   Shanghai 's CARsgen presented positive early clinical data of a first-in-class CAR-Claudin18.2 T cell trial in patients with pancreatic and gastric cancer; Innovent Biologics of Suzhou announced that China 's NMPA has approved an IND application for its anti-CD47 mAb in multiple tumor types; Shanghai 's EpimAb Biotherapeutics filed US and China INDs simultaneously for a bispecific antibody that targets EGFR and cMET receptors. Stock Symbols: (NSDQ: BCAC) (HK: 2552) (NSDQ: YI) (SHA: 600535) (SHA: 601607) (NSDQ: ZLAB) (NSDQ: NVCR) Share this with colleagues: // //